key: cord-0794004-8rppxj1o authors: Xia, Qingchang; Gao, Huawei; Xian, Jin; Yan, Xiao; Zhou, Yue; Lu, Yunping; Ma, Yuxia title: Efficacy and safety of acupuncture for elderly patients with coronavirus disease 2019 (COVID-19): A protocol for systematic review and meta-analysis date: 2021-02-05 journal: Medicine (Baltimore) DOI: 10.1097/md.0000000000024515 sha: 4b5976a7abaad282b5ffa60024b5b710d3f41798 doc_id: 794004 cord_uid: 8rppxj1o BACKGROUND: The study aims to evaluate the effectiveness and safety of acupuncture therapy for elderly patients with coronavirus disease 2019 (COVID-19). METHODS: Relevant articles from December 2019 to December 2020 will be searched in the following electronic databases: Medline, PubMed, EMBASE, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), China Biomedical Literature Database (CBM), and China Scientific Journals Database. All published randomized controlled trials (RCTs) and credible clinical observations about this topic will be included. Two independent researchers will operate article retrieval, duplication removing, screening and data analysis by EndNote X9.0 and Stata 15.0. We will use the Cochrane risk of bias tool for randomized trials to assess the risk of bias of included studies. Meta-analysis, subgroup analysis, and/or descriptive analysis will be performed according to the data conditions included. RESULTS: High-quality synthesis and/or descriptive analysis of current evidence will be provided from mortality rate, cure rate, C-reactive protein (CRP), creatine, troponin, aspartate aminotransferase, alanine aminotransferase, and improvements in chest CT scans, clinical symptoms (including fever, fatigue, cough, nausea, vomiting and diarrhea) and the side effects of acupuncture. CONCLUSION: This study will provide evidence of whether acupuncture is an effective and safe intervention for the elderly with COVID-19. PROSPERO REGISTRATION NUMBER: CRD42020225245. In December 2019, the first case of COVID-19 was found in Wuhan, China. [1, 2] Subsequently, COVID-19 quickly broke out around the world, causing serious complications and death, and causing panic and anxiety among people all over the world. [3, 4] By December 2020, China reported the cumulative number of infections was nearly 70 million, and the cumulative death toll was nearly 1.6 million. Current studies have found that COVID-19 poses a serious health threat to the elderly. [5] [6] [7] [8] [9] [10] Elderly men with higher body mass index, high respiratory rate and underlying diseases (such as hypertension, diabetes, cardiovascular disease and chronic obstructive pulmonary disease) are more likely to develop severe COVID-19 infection. The main symptoms are fever and dyspnea. Laboratory tests showed that the number of white blood cells was higher in the elderly group than in the young patients, and the number of lymphocytes was lower in the young patients. [10, 11] The lack of effective treatments for COVID-19 at home and abroad, especially for the elderly, which has made the COVID-19 pandemic the most serious global public health crisis. [12] [13] [14] QX and HG contributed equally to this work. This work was supported by the National Natural Science Foundation of China (No. 81774402). The authors state that they have no conflicts of interest. All data generated or analyzed during this study are included in this published article [and its supplementary information files]. College of Acupuncture and Massage, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China. As is known to all, COVID-19 has been well controlled in China, mainly due to the joint efforts of Chinese and western medicine, especially Chinese medicine, which has made outstanding contributions to improving patients' symptoms and promoting recovery. [15] [16] [17] [18] Acupuncture, as one of the traditional Chinese medicine treatment, has the advantage of quick effect, simple operation, and less pain, etc. Studies have shown that it can improve symptoms of dyspnea, relieve anxiety, treat insomnia, vomiting, and diarrhea, etc. so it has been widely used in the prevention, treatment and rehabilitation of patients with COVID-19. [19] [20] [21] [22] [23] [24] According to published studies, there is a lack of high-quality evidence on acupuncture for the elderly with COVID-19. Therefore, this systematic review aims to evaluate the effectiveness and safety of acupuncture in the treatment of elderly patients with COVID-19. This systematic review protocol has been registered in the PROSPERO network (No. CRD42020225245). And it will follow recommendations outlined in The Cochrane Handbook of Systematic Review of Interventions. RCTs and credible clinical observations without any limitation of blinding or publication language will be included. Animal studies, reviews, case reports, meta-analyses, and republished papers will be excluded. Elderly patients (≥60 years) diagnosed with COVID-19 and receiving acupuncture treatment will be included, with no restrictions on gender, race, nationality or disease. [25] Observation group: Types of acupuncture, moxibustion, electroacupuncture, fire needle, warming needle moxibustion, acupoint injection and auricular therapy will be included. Control group: Any method other than acupuncture will be included, such as placebo, Traditional Chinese medicine, Western medicine and non-intervention, etc. Primary outcomes will include mortality rate, cure rate, Creactive protein (CRP), creatine, troponin, aspartate aminotransferase, alanine aminotransferase, and improvements in chest CT scans. Secondary outcomes will include the disappearance time of clinical symptoms (including fever, fatigue, cough, nausea, vomiting and diarrhea) and the side effects of acupuncture. Relevant articles from December 2019 to December 2020 will be searched in the following electronic databases: Medline, PubMed, EMBASE, Web of Science, Cochrane Library, CNKI, CBM, China Scientific Journals Database, etc. The complete Medline search strategy is summarized in Table 1 . According to different databases, keywords can be combined with free words for comprehensive search. 2.7. Data collection and analysis 2.7.1. Selection of studies. Two reviewers (QCX and HWG) will screen the study independently and check the results with each other. When disagreements occur, the third examiner (YZ) will make the final decision. If necessary, they will read the full text of all included study. If complete literature or relevant data is not available, we will contact the corresponding author. The filter operation process will be shown in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols flow diagram (Fig. 1 ). Two reviewers (XY and YZ) will assess the quality and risk of bias of the included articles according to the Cochrane Handbook. Quality assessment of included studies contains random sequence generation, allocation concealment, blindness to outcome assessment, blindness of participants and personnel, incomplete outcome data, selective reporting and other biases. Based on the research assessment of these seven areas, they will be classified as "low risk", "high risk" or "unclear risk" bias. A third reviewer (QCX) will be consulted if there is an assessment disagreement. Two independent reviewers (QCX and HWG) will extract the evaluated article data with a standardized data extraction form, and when they have differences of opinion, they will discuss them with a third reviewer (YXM) if they can not resolve them. The data will be recorded onto an electronic form, including general information about the article (first author, title, year and language), inclusion and exclusion criteria, baseline of All efficacy data will be transferred to Stata 15 for analysis and synthesis. For continuous results, the data will be presented by mean difference (MD) or standard mean difference (SMD) with 95% confidence intervals (CIs). When dichotomous data exists, risk ratio (RR) with a 95% CI will be used. When binary data exists, the RR form will be changed for analysis. Dealing with missing data. If the data is lost in the literature, we will contact the corresponding author by email or other means. If the missing data is not available, we will exclude these articles and integrate the rest of the research. 2.7.6. Assessment of heterogeneity. The included studies will use the chi-square test and Q test to evaluate the heterogeneity. If I 2 < 50%, the heterogeneity of the text will be ignored and the fixed-effect model will be used. If I 2 ≥ 50%, statistical heterogeneity will be considered to be significant, the random-effect model will be adopted. [26] 2.7.7. Assessment of reporting bias. We will use the funnel plot and Egger test to assess publication bias if >10 articles are included. 2.7.8. Data synthesis. We will use the Stata 15.0 software for meta-analysis. If the clinical and methodological heterogeneity is low, fixed-effect models will be used. If heterogeneity is significant, we will use the random-effects model and perform subgroup analysis or descriptive analysis. 2.7.9. Subgroup analysis. Subgroup analysis will be performed based on the results of the data synthesis, if necessary, we will conduct subgroup analysis of any source of heterogeneity. 2.7.10. Sensitivity analysis. The sensitivity analysis will be performed by using Leave 1 out. We will plan to conduct a sensitivity analysis of the main results to figure out whether the results are affected by the use of different analytical methods (random-effects model or fixed-effects model) and to confirm the robustness of our results. 2.7.11. Quality of evidence. Two reviewers (JX and YPL) will independently evaluate the quality of evidence by using the Grading of Recommendations Assessment, Development and Evaluation (GRADE). We will evaluate the quality of evidence as "high," "moderate," "low," or "very low" according to five parameters (publication bias, indirectness, inconsistency, imprecision, and study limitations). A third reviewer (QCX) will be consulted if quality ratings are not consistent between the two reviewers. Because no data in this review are relevant to individual patients, ethical approval is not required for this study. The highly infectious and pathogenic characteristics of COVID-19 have made it spread rapidly around the world. It not only endangers the health of the public, but also causes major damage to the world's economic development. Elderly people with poor resistance, in particular, are the preferred targets for COVID-19. Therefore, how to protect the lives of the elderly in the epidemic situation has become a research hotspot in the current medical field. As one of the traditional Chinese medicine treatment methods, acupuncture can not only be used to prevent the disease before it occurs, but also be used as an auxiliary treatment after it occurs. If there is evidence that acupuncture works for the elderly with COVID-19, it will benefit the world. Thus, a systematic review about it is urgently needed. This study could provide evidence for acupuncture treatment on elderly patients with COVID-19 and help clinicians make decisions. Epidemiological characteristics and clinical features of patients infected with the COVID-19 virus in Nanchang Epidemiological and clinical characteristics of fifty-six cases of COVID-19 in Liaoning Province Anxiety and suicidal thoughts during COVID-19 pandemic: a cross-country comparison among Indonesian, Taiwanese, and Thai university students Psychological distress in the face of a pandemic: An observational study characterizing the impact of COVID-19 on immigrant outpatient mental health Comprehensive review of implications of COVID-19 on clinical outcomes of cancer patients and management of solid tumors during the pandemic Clinical characteristics and survival analysis in critical and non-critical patients with COVID-19 in Wuhan, China: a single-center retrospective case control study Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) Outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention Clinical characteristics of older patients infected with COVID-19: a descriptive study Characteristics and clinical outcomes of COVID-19 patients in an underserved-inner city population: A single tertiary center cohort Understanding the clinical features of coronavirus disease 2019 from the perspective of aging: a systematic review and metaanalysis Risk factors for 2019 novel coronavirus disease (COVID-19) patients progressing to critical illness: a systematic review and meta-analysis Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses Coronavirus infections-more than just the common cold Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19) Identifying potential treatments of COVID-19 from Traditional Chinese Medicine (TCM) by using a data-driven approach Therapeutic options of TCM for organ injuries associated with COVID-19 and the underlying mechanism Acupuncture plus Chinese Herbal Medicine for Irritable Bowel Syndrome with Diarrhea: A Systematic Review and Meta-Analysis. Evid Based Acupuncture for breathlessness in advanced diseases: methodological issues Acupuncture for breathlessness in advanced diseases: a systematic review and meta-analysis Manual acupuncture versus sham acupuncture and usual care for prophylaxis of episodic migraine without aura: multicentre, randomised clinical trial Effect of acupuncture on pregnancy-related insomnia and melatonin: a single-blinded, randomized, placebo-controlled trial Acupuncture therapy on postoperative nausea and vomiting in abdominal operation: A Bayesian network meta analysis Is endoscopic retrograde cholangiopancreatography safe during pregnancy?